Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy- -Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall
View HTML
Toggle Summary Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
-Approval Triggers Milestone Payment to Seattle Genetics of $10 Million - BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 21, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry
View HTML
Toggle Summary Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 4, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT . The presentation will be webcast live and available for replay
View HTML
Toggle Summary Seattle Genetics Reports Second Quarter 2018 Financial Results
-Record ADCETRIS ®  (Brentuximab Vedotin) Net Sales in U.S. and Canada of $122.4 Million in the Second Quarter- -ADCETRIS ECHELON-2 Top-line Results Expected in Early Fourth Quarter 2018- -Enrollment Completed in Pivotal Trial Cohort of Enfortumab Vedotin in Metastatic Urothelial Cancer; EV
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
-Trial to Inform Broader Development Program Strategy- -Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 12, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the
View HTML
Toggle Summary Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
Results of Combination “Triplet” of Tucatinib with Trastuzumab and Capecitabine Published in The Lancet Oncology Results of Tucatinib in Combination with Ado-trastuzumab Emtansine Published in JAMA Oncology BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 11, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed- -First Patient Dosed in Phase 3 Global Confirmatory Trial- BOTHELL, Wash. & TOKYO --(BUSINESS WIRE)--Jul. 9, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 26, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Jun. 28, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 26, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
-Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment- -Tisotumab Vedotin Represents Fourth Late-Stage Development Program Added to List of Ongoing Pivotal Trials Along with Enfortumab Vedotin and Tucatinib- BOTHELL, Wash.
View HTML